TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Allogeneic hematopoietic cell transplantation represents the only treatment option capable of offering a cure to patients with myelodysplastic syndrome. Here, we demonstrate that presence of mutations in TP53 and IDH2 in myelodysplastic syndrome confer a poor prognosis even in the setting of allogeneic transplantation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Mohamed A. Kharfan-Dabaja, Rami S. Komrokji, Qing Zhang, Ambuj Kumar, Athanasios Tsalatsanis, Janelle Perkins, Taiga Nishihori, Teresa Field, Najla Al Ali, Asmita Mishra, David Sallman, Karma Z. Salem, Ling Zhang, Lynn Moscinski, Hugo F. Fernandez, Jeffre Tags: Original Study Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Study | Transplants